Adobe
By Meghana Keshavan
April 30, 2026
Biotech Correspondent
Meghana Keshavan
Five-way obesity drug is super effective — in mice
A 'quintuple agonist,' Alector halts it Alzheimer's trial, and more biotech news from The Readout
331 words~2 min read
Related reading
What obesity drugmakers see next in the market: More pills, easier access and…
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference…
GLP-1s could end up being ‘the first true longevity drug’ as the world battles…
Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up…
The highest dose of Eli Lilly's weekly injection helped patients with obesity or who are overweight lose 20.1% of their body…
This biotech name is evolving into a major obesity play. How to trade it with…
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces…
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound…
Axsome wins FDA nod for Alzheimer's agitation
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout